MTNB - Matinas BioPharma Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.497
-0.003 (-0.60%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.500
Open0.500
Bid0.410 x 1000
Ask0.000 x 900
Day's Range0.480 - 0.520
52 Week Range0.432 - 2.790
Volume376,778
Avg. Volume321,389
Market Cap46.736M
Beta1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.169
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Matinas BioPharma Announces Pricing of $8.0 Million Public Offering

    Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today announced the pricing of a public offering of up to 8,000 shares of its newly designated Series B Convertible Preferred Stock, or the Series B Preferred, with a stated value of $1,000 per share and convertible into an aggregate of 16,000,000 shares of its common stock at a conversion price of $0.50 per share. Holders of the Series B Preferred will be entitled to receive dividends payable in shares of common stock equal to (i) 10% of the shares of common stock underlying the Series B Preferred then held by such holder on the 12-month anniversary of the offering, (ii) 15% of the shares of common stock underlying the Series B Preferred then held by such holder on the 24-month anniversary of the offering and (iii) 20% of the shares of common stock underlying the Series B Preferred then held by such holder on the 36-month anniversary of the offering.

  • GlobeNewswire10 days ago

    Matinas BioPharma to Present at the 20th ICHS Symposium on Infections in the Immunocompromised Host

    Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today announced that Jerome D. Jabbour, Chief Executive Officer of Matinas, will present at the 20th  International Immunocompromised Host Society (ICHS) Symposium on Infections in the Immunocompromised Host, being held June 17-19, 2018 in Athens, Greece. The ICHS Symposium is the premier, international, multi-disciplinary forum for scientific and clinical interchange to improve understanding and management of the immunocompromised host and is hosted by Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FACP, FIDSA, FECMM, FAAM, FAAAS.

  • Matinas BioPharma Holdings Inc (NYSEMKT:MTNB): Is Breakeven Near?
    Simply Wall St.15 days ago

    Matinas BioPharma Holdings Inc (NYSEMKT:MTNB): Is Breakeven Near?

    Matinas BioPharma Holdings Inc’s (AMEX:MTNB): Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing antifungal and anti-bacterial therapeutics for the treatment of various infections in theRead More...

  • GlobeNewswire16 days ago

    Matinas BioPharma to Present Preclinical Data at ASM Microbe 2018 Further Demonstrating the Broad Utility of its LNC Platform

    Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today announced it will present data in two poster sessions at The American Society for Microbiology’s ASM Microbe 2018 scientific meeting being held June 7–11 in Atlanta, GA. “We continue to explore the broad capabilities of our LNC technology platform as we advance our lead product candidate, MAT2203, towards a potential Phase 2 pivotal trial for prevention of invasive fungal infections (IFIs) in patients with acute lymphoblastic leukemia (ALL).

  • GlobeNewswirelast month

    Matinas BioPharma Reports First Quarter 2018 Financial Results and Provides Corporate Update

    –Management to host conference call with live audio webcast today, Thursday, May 10 th at 8:30 am EDT–. BEDMINSTER, N.J., May 10, 2018-- Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical ...

  • GlobeNewswire2 months ago

    Matinas BioPharma to Host Quarterly Update Conference Call

    Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (“LNC”) platform delivery technology, today announced that it will report its financial results for the quarter ended March 31, 2018 in a press release that will be issued pre-market on Thursday, May 10, 2018. The Company also announced that it will host a conference call with live audio webcast that same day at 8:30 AM EDT. During the conference call, Jerome D. Jabbour, Chief Executive Officer, will review the Company’s operational progress and expected near-term milestones.

  • GlobeNewswire2 months ago

    Matinas BioPharma Selected to Present at the BioNJ Eighth Annual BioPartnering Conference

    BEDMINSTER, N.J., May 01, 2018-- Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on developing innovative medicines using its proprietary lipid nano-crystal platform ...

  • GlobeNewswire2 months ago

    Matinas BioPharma to Present Positive Preclinical Data of MAT2203 at the 28th European Congress of Clinical Microbiology and Infectious Disease

    Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that it will present a poster at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held April 21-24, 2018, in Madrid, Spain. The Company’s lead product candidate, MAT2203, is an orally-administered cochleate formulation of a broad spectrum anti-fungal drug called amphotericin B. Matinas is initially developing MAT2203 for the prevention of invasive fungal infections due to immunosuppressive therapy, particularly in patients with acute lymphoblastic leukemia.

  • GlobeNewswire3 months ago

    Matinas BioPharma Reports 2017 Financial Results

    BEDMINSTER, N.J., March 26, 2018-- Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today formally announced ...

  • ACCESSWIRE3 months ago

    Matinas BioPharma Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 19, 2018 / Matinas BioPharma Holdings, Inc. (NYSE American: MTNB ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 19, 2018, at ...

  • ACCESSWIRE10 months ago

    Investor Network: Matinas BioPharma Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Matinas BioPharma Holdings, Inc. (NYSE American: MTNB ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, ...

  • Here's Why Matinas BioPharma Holdings Inc. Is Losing Ground Today
    Motley Foollast year

    Here's Why Matinas BioPharma Holdings Inc. Is Losing Ground Today

    Matinas BioPharma's lead candidate failed to hit the mark in a mid-stage trial.